Format

Send to

Choose Destination
J Immunol. 2014 Jul 15;193(2):580-586. doi: 10.4049/jimmunol.1400118. Epub 2014 Jun 13.

Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.

Author information

1
University of California, San Francisco, Department of Neurology, San Francisco, CA, USA.
2
Department of Neurology, University Hospital, Basel, Switzerland.
#
Contributed equally

Abstract

In multiple sclerosis (MS), B cell-depleting therapy using monoclonal anti-CD20 Abs, including rituximab (RTX) and ocrelizumab, effectively reduces disease activity. Based on indirect evidence, it is generally believed that elimination of the Ag-presenting capabilities and Ag nonspecific immune functions of B cells underlie the therapeutic efficacy. However, a small subset of T lymphocytes (T cells) was shown to also express CD20, but controversy prevails surrounding the true existence of this T cell subpopulation. Using single-cell imaging flow cytometry and expression profiling of sorted lymphocyte subsets, we unequivocally demonstrate the existence of CD3(+)CD20(dim) T cells. We show that in MS patients, increased levels of CD3(+)CD20(dim) T cells are effectively depleted by RTX. The pathological relevance of this T cell subset in MS remains to be determined. However, given their potential proinflammatory functionality, depletion of CD20-expressing T cells may also contribute to the therapeutic effect of RTX and other mAbs targeting CD20.

PMID:
24928997
PMCID:
PMC4082756
DOI:
10.4049/jimmunol.1400118
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center